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twins and associated differences in blood
DNA methylation
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Abstract
Background: Lung function is an important predictor of morbidity and mortality, with accelerated lung function
decline reported to have immense consequences for the world’s healthcare systems. The lung function decline
across individual’s lifetime is a consequence of age-related changes in lung anatomical structure and combination
of various environmental factors; however, the exact molecular mechanisms contributing to this decline are not
fully understood. DNA methylation is an epigenetic modification that changes across individual’s lifetime, as well as
allows for interplay between environmental and genetic factors. DNA methylation plays a crucial role in regulation
of gene expression, with increasing evidence linking aberrant DNA methylation levels with a number of common
human diseases. In this study, we investigated possible associations between genome-wide DNA methylation levels
and lung function in 169 pairs of middle-aged monozygotic twins (86 male pairs: mean age (min-max) = 66 years
(57–79); 83 female pairs: mean age (min-max) = 66 years (56–78)). The twins were collected from the Danish Twin
Registry and were examined at baseline (1998–1999) and follow-up (2008–2011) visits. Using the twin design, we
correlated intra-pair differences in cross-sectional and longitudinal lung function with intra-pair blood DNA
methylation differences at follow-up by linear regression analyses adjusted for sex, age, BMI, smoking, and blood
cell composition measured for each individual with the use of flow cytometry.
Results: We identified several differentially methylated CpG sites associated with forced expiratory volume the first
second (FEV1) and forced vital capacity (FVC). Three probes identified for level of FVC were located in GLIPR1L2
gene (lowest p value = 7.14 × 10−8), involved in innate immunity and tumour-suppressor/pro-oncogenic mechanisms.
Change in FEV1 during the 11-year follow-up period was associated with blood DNA methylation level in TRIM27 gene
(p value = 1.55 × 10−6), a negative regulator of CD4 T cells, and also involved in cancer development. Several enriched
pathways were identified, especially for FEV1, with one being “TGFBR” (Benjamini-Hochbergadj p value = 0.045),
the receptor for TGFβ, a growth factor involved in normal lung tissue repair through pro-fibrotic effects.
Conclusions: Our findings suggest that epigenetic regulation of immunological- and cancer-related genes, as well as
TGF-β-receptor-related genes, may be involved in the cross-sectional level and longitudinal change in lung function in
middle-aged monozygotic twins.
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Background
Accelerated decline in lung function and associated
diseases can have immense consequences for the indi-
vidual and profound economic and social consequences
for society [1, 2]. Lung function is an important pre-
dictor of morbidity and mortality [3], as well as cognitive
and physical well-being in the general population [4].
Even though lung function slowly and continuously
declines with age in adulthood [5], an accelerated
decline in lung function is associated with chronic
pulmonary diseases, such as asthma and chronic
obstructive pulmonary disease (COPD). Both diseases
impose a high burden on society; COPD is estimated
to be the third leading cause of death worldwide [6],
and the prevalence of asthma is increasing, now
affecting more than 10% of the population in some
developed countries [1].
Age-dependent lung function decline is a conse-
quence of anatomical structural changes, such as de-
creased lung recoil and decreased respiratory muscle
strength, in combination with physiological and im-
munological changes [7]. Furthermore, factors such as
smoking [8] and various occupational exposures [9]
are known to lead to an accelerated decline in lung
function.
Studies on monozygotic (MZ) and dizygotic twins
have previously shown a substantial genetic compo-
nent influencing level of lung function, with heritabil-
ity estimates for forced expiratory volume in the first
second (FEV1) ranging from 61 to 69%, and for
forced vital capacity (FVC) from 55 to 63% [10, 11].
Part of this heritability is linked to body composition,
such as height and chest size [12]. Furthermore, sev-
eral genome-wide association studies (GWAS) have
identified numerous genetic variants associated with
lung function level and change [13–15], as well as
identified important integrative pathways for lung
function and airflow obstruction [16, 17]. However, as
environmental factors are also known to impact indi-
vidual’s lung function, novel molecular mechanisms,
such as epigenetics, may help understand the variance
in liability and systems biology responsible for change
in lung function across lifetime.
Epigenetics, literally meaning “beyond the genetics”,
is the science of heritable changes in gene regulation
and expression that do not involve changes to the
underlying DNA sequence. Epigenetic modifications,
such as DNA methylation and histone modifications,
alter chromatin structure and DNA accessibility and
thereby regulate patterns of gene expression in the
genome [18–25]. The most widely studied epigenetic
modification is DNA methylation, which primarily oc-
curs at CpG sites [26]. Direction of correlation be-
tween DNA methylation and gene expression is
dependent on the genomic context. Overall, DNA
methylation in promoter regions and at repetitive ele-
ments is associated with decreased gene expression,
in gene bodies with increased expression, while its
presence in intergenic or 3′-untranslated regions is
associated with upregulation of some transcripts and
downregulation of others [19, 26–32]. Genome-wide
DNA methylation patterns change along lifetime due
to environmental, as well as stochastic factors
impacting epigenome [33]. The dynamic nature of
this epigenetic modification is possible due to two
main groups of enzymes, DNA methyltransferases
(DNMTs) and ten-eleven translocation (TET) pro-
teins, responsible for addition, maintanance, and re-
moval of methyl groups from DNA sequences at a
pre-designed manner [34–39]. Improper functioning
of this writing, reading, and erasing epigenetic ma-
chinery is associated with development and progres-
sion of multiple diseases, such as diabetes, cancer,
and neurodegenerative and mental disorders [40–46].
Moreover, differences in DNA methylation levels be-
tween MZ discordant twins were associated before
with several common disorders, including cancer,
autoimmune diseases, diabetes, as well as mental dis-
orders [47–51].
There are various environmental factors that may
influence lung function and epigenetic modifications
along lifetime, with smoking considered to be a strong
environmental modifier of DNA methylation [52–54]
and histone modifications [55–58], as well as the great-
est predictor of lung function decline [8]. Several studies
[52, 59] have found effects of smoking to be associated
with both hypo- and hyper-methylation signatures de-
pending on the CpG site, although global hypo-
methylation seems to dominate in smokers [52, 60].
Only few studies have explored the association between
DNA methylation and the cross-sectional level and
longitudinal change in lung function. Significant
associations have been found between methylation of
the inflammatory genes CRAT, F3, TLR2, IFNγ, and
IL6, as well as SERPINA1, ATP6V1E2, FXYD1, FUT7,
STAT5A, TRPM2, and LRP3, and lung function [61, 62].
Also, the methylation of the repetitive elements Alu
and LINE-1 was found to be associated with lung
function [63].
In this study, we performed an epigenome-wide
association study (EWAS) between lung function and
genome-wide DNA methylation levels using a study
sample of 169 middle-aged MZ twin pairs, thus enab-
ling us to control for underlying genetic and shared
environmental factors. We explored blood DNA
methylation signatures in association with both cross-
sectional lung function level and long-term change in
lung function during an 11-year follow-up period.
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Methods
The studied population is a sub-population of twins from
the middle-aged Danish twin (MADT) study [64] col-
lected as a part of the Danish Twin Register (DTR) [65].
MADT was initiated with a baseline survey in 1998–1999
as a Danish nation-wide study of 4314 twins randomly se-
lected from birth cohorts spanning 1931–1952 [64]. A
follow-up study was conducted in 2008–2011 of all eli-
gible twin pairs (9.9% deceased) originally enrolled [66].
The present study included 169 MZ twin pairs (83 female
and 86 male pairs) that participated at both baseline and
follow-up and with full data available.
Lung function was assessed for all participants at
baseline at the participant’s home [10] and at the
follow-up approximately 11 years later (min-max 9.6–
13.4 years) at five study centres [66]. The three lung
function measures FEV1, FVC, and the ratio FEV1/
FVC (differentiating between obstructive and restrict-
ive pulmonary disease) were assessed by spirometry
using the micro DL device at baseline and “EasyOne”
device at follow-up. The quality of each attempt was
evaluated, and the highest obtained spirometry values
out of three acceptable attempts for each individual
were accepted and included for further analyses ac-
cording to spirometry guidelines [67]. Height and
weight was self-reported at baseline and measured at
follow-up. Body mass index (BMI) was calculated at
both time points as weight (kg) divided by height
squared (m2). At follow-up, whole blood samples were
collected from all participants. Informed written con-
sent was obtained from all participants. Written
informed consents obtained from all participants and
the surveys, including collection of blood and use of
survey information, were approved by the Regional
Committees on Health Research Ethics for Southern
Denmark (S-VF-19980072).
In order to standardize each participant’s individual
lung function, the important predictors sex, age,
height, and ethnicity, as well as the lung function
measures of the individual, were applied to the
GLI2012 equations [68] providing z-scores for FEV1,
FVC, and FEV1/FVC for both baseline and follow-up
measures. The standardized z-scores hence describe
how many standard deviations (SDs) an individual’s
lung function is away from the lung function of a
healthy, non-smoking reference population of same
sex, age, height, and ethnicity. We used follow-up
height for both baseline and follow-up z-score calcu-
lations, as height was only objectively measured at
the follow-up visit. Moreover, for this middle-aged
group of twins, it was not expected that changes in
height during the follow-up period would occur. Cal-
culation of change in z-score during the follow-up
period for all three lung function measures was done
by subtracting the baseline z-score from the follow-up
z-score.
Intra-pair (IP) differences in z-score for level of lung
function (ΔzFEV1IP, ΔzFVCIP, ΔzFEV1/FVCIP) were cal-
culated for follow-up values as the absolute difference in
e.g. zFEV1 between the “superior” twin (the twin with
higher zFEV1) and the “inferior” twin (the twin with
lower zFEV1):
ΔzFEV1IP ¼ zFEV1superiorzFEV1inferior
Similarly, ΔzFVCIP and ΔzFEV1/FVCIP were calcu-
lated as the difference between the “superior” and the
“inferior” twin, respectively. The same was calculated for
intra-pair differences of the changes in lung function z-
scores during the follow-up period (ΔzFEV1-changeIP,
ΔzFVC-changeIP, ΔzFEV1/FVC-changeIP).
All analyses were adjusted for smoking status and
smoking history of the investigated twins. Smoking
was expressed as pack years (equal to 20 cigarettes/
day × years) in total and during the follow-up period.
Participants were also divided into current smokers,
non-current smokers, and never smokers at follow-up.
Smokers who quit smoking less than 2 years prior to
assessment were defined as current smokers at the
time of assessment in order to account for smoking
effects that persist for some time after smoking
cessation.
DNA methylation analysis
The semi-automated salt precipitation protocol with
Autopure System (Qiagen) was used to extract genomic
DNA from leukocytes in the buffy coat. Genomic DNA
(500 ng/sample) was bisulfite-converted with EZ Methy-
lation Gold Kit (Zymo Research) and analysed using the
Infinium HumanMethylation450 BeadChips (Illumina)
array according to the manufacturer’s protocol. Quality
control for obtained DNA methylation data was
performed with two different pipelines, a combination of
MethylAid [69] and minfi tools [70]. Probes with low
bead count (< 3 beads), high detection p value (> 0.01),
and zero signal and missing in > 5% of samples were re-
moved from further analysis. Additionally, cross-reactive
probes identified previously by Chen et al. [71] were
removed from the dataset. Four hundred fifty-three
thousand fourteen good quality probes remained for
further EWAS analyses. Normalisation of DNA methyla-
tion data, in order to control for technical variation, was
done with the use of functional normalization
(FunNorm) [72], and obtained β values (the proportion
of DNA methylation) were further logit-transformed
giving M values for each probe.
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Blood cell composition
Blood cell counts were measured from the same blood
samples that were used for DNA methylation profiling.
Blood cell counts were available for 332 individuals, for
which blood leukocyte subtypes (monocytes, lymphocytes,
basophils, neutrophils, and eosinophils) were counted
using a Coulter LH 750 Haematology Analyser. Blood cell
counts were not available for six individuals, and thus,
they were imputed based on the methylome dataset as
described previously by van Iterson, pipeline provided on
GitHub [73]. Blood cell counts were used to adjust for
individual differences in cellular heterogeneity in blood
sample from which genomic DNA was extracted.
Statistical analyses
Distributions of data were evaluated using histograms
and quantile-quantile plots. For normally distributed
data, mean ± SD was reported, and comparisons were
made using Student’s t test. For non-normally distrib-
uted data, median (min-max) was reported and a Mann-
Whitney (Wilcoxon) rank-sum test was used to compare
groups with unequal variance.
Epigenome-wide association study (EWAS) analyses
were performed for intra-pair (IP) differences of
both cross-sectional and longitudinal lung function
z-scores.
The intra-pair differences in DNA methylation level (M
value) for each probe was calculated as the “superior”
minus the “inferior” twin in accord with the explanatory
variable (e.g. ΔzFEV1ip). The same was done for all other
included variables for each twin pair. In EWAS analyses,
using linear regression models, associations between
intra-pair DNA methylation difference and both the
cross-sectional and the longitudinal intra-pair lung func-
tion difference were investigated. The z-score of lung
function can be seen as a relative measure, as it implies
the state of the individuals’ lung function, compared to
the state expected from the reference population (GLI
2012 [68]). With that consideration and also due to the
distribution of z-scores, which is around 0, we took the
intra-pair difference in z-score as a measurement of quan-
titative discordance, instead of calculating the proportion
of discordance between twins as done in previous studies
of birth weight discordant MZ twins [74, 75].
All regression models were adjusted for sex, age, BMI,
ever smoking history (total pack-years), and smoking
status at follow-up, as well as blood cell composition
difference within each twin pair. The longitudinal
models were additionally adjusted for BMI change
during the follow-up period (instead of cross-sectional
BMI) and smoking pack-years during the follow-up
period (instead of total pack-years).
Log transformation was applied to independent vari-
ables with extremely skewed distributions (IP differences
of zFEV1, zFVC, zFEV1-change, and zFVC-change). All
analyses were performed in R (http://www.R-project.org/)
or STATA14 (StataCorp. 2015. Stata Statistical Software:
Release 14. College Station, TX: StataCorp LP).
Results with a p value < 10−6 were reported as signifi-
cant in this study (as suggested to be the genome-wide
significant threshold for EWAS [76]). The level of
significance for the corresponding false-discovery rate
(FDR)-adjusted p value was < 0.05. Results from EWAS
with a p value < 10−5 were presented in tables.
In order to explore if associated genes were overrepre-
sented in specific pathways, pathway enrichment ana-
lyses were performed. Kyoto Encyclopaedia of Genes
and Genomes (KEGG), Gene Ontology (GO) pathway,
and Pathway Commons (PC) enrichment with the WEB-
based GEne SeT AnaLysis Toolkit (WebGestalt) [77]
were used against the genes included in the 450K DNA
methylation array. Probes from EWAS with an
unadjusted p value < 10−5 were used for pathway enrich-
ment analyses. p values from pathway enrichment ana-
lyses were corrected for multiple testing with the
Benjamini-Hochberg (BH) correction method [78].
Results
A total of 169 twin pairs (83 female and 86 male
pairs) with a mean age at follow-up of 66 years (min-
max 56–79 years) were available with complete details
on lung function measurements at baseline and
follow-up, sex, age, height, smoking history, and DNA
methylation data. Table 1 shows the demographics of
the participants.
In Table 2, the lung function values are presented as
absolute lung function values, z-score values, and change
in z-score during the follow-up period for the popula-
tion. Furthermore, calculated intra-pair differences in z-
scores at follow-up are given, as well as the intra-pair
differences in change in z-score during the follow-up
period. As expected, males and females differed in abso-
lute values for FEV1 and FVC, whereas standardized
Table 1 Demographics of the cohort of MZ twin pairs included
in this study
Male (n = 172) Female (n = 166)
Participating twin pairs 86 83
Age, years 66 (57–79) 66 (56–78)
Follow-up time, years 11.0 (9.6–13.2) 11.0 (9.8–13.4)
Height, cm 174.0 (158.8–194)* 161.9 (148.5–176.2)
Weight, kg 81.9 (56.2–118.8)* 67.7 (35–102.9)
BMI, kg/m2 27.0 (19.3–38.0)* 25.5 (13.8–38.1)
Smoking, pack-years
(mean ± SD)
20.8 ± 26.9* 7.3 ± 12.8
Numbers are stated as median (min-max) unless otherwise specified
*p < 0.05 between male and female
Bolund et al. Clinical Epigenetics  (2017) 9:132 Page 4 of 13
measures of lung function (z-scores) showed no signifi-
cant difference between the sexes. Absolute lung func-
tion measures declined during the follow-up period
(Table 2). The observed decrease was slightly higher in
males in comparison to females; however, it was not
higher relative to the baseline value, for which both
males and females decreased with 13% in FEV1 and 5%
in FVC during the 11 years of follow-up (data not
shown). The variance of intra-pair difference in lung
function tended to be higher in male twin pairs in com-
parison to female twin pairs—possibly due to greater
discordance in smoking history between male twins than
between female twins (mean difference of 14 pack-years
vs. 8 pack-years (p < 0.05), respectively, for smoking dis-
cordant twin pairs).
Tables 3 and 4 present results from EWAS analyses
for intra-pair difference in level of lung function at
follow-up and for intra-pair difference in change in
lung function during the follow-up period, respect-
ively. All probes with p value < 10−5 were annotated
with the most proximal gene, genomic position, and CpG
island context (according to Human Genome Issue
hg19) and are presented together with regression esti-
mates and p values.
Manhattan plots depicting results from all six
EWAS analyses are presented in Fig. 1a-f. In
Additional file 1: Fig. S1A-F, the corresponding Q-Q
plots are presented.
In regressing intra-pair DNA methylation differences
on intra-pair differences in lung function at follow-up,
nine CpG sites with a p value < 10−5 were found for
zFEV1 (log-ΔzFEV1IP) (Table 3) with no sites reaching
a p value < 10−6. For intra-pair difference in zFVC
(log-ΔzFVCIP), ten sites with a p value < 10
−5 were
identified (Table 3), with the most significant probe
identified as cg02071292 annotated to GLI (glioma)
pathogenesis-related 1-like 2 (GLIPR1L2) with a p value =
7.14 × 10−8 (FDRadj p value = 0.03). Two other probes with
a p value < 10−5 in this analysis were also annotated to
GLIPR1L2 (cg07311024 p value = 1.96 × 10−6 and
cg15942481 p value = 8.77 × 10−6). Intra-pair difference in
level of zFEV1/FVC (log-ΔzFEV1/FVCIP) identified 11
CpG sites with the only probe reaching a p value < 10−6
mapping to no currently known gene (cg00995220,
located on chromosome 6) (Table 3).
Regressing intra-pair DNA methylation differences
on change in zFEV1 (log-ΔzFEV1-changeIP) resulted
in two findings of p value < 10−5 (Table 4), with the
most associated probe cg19484381 mapping to
tripartite motif containing 27 (TRIM27) with a
p value = 1.55 × 10−6. Intra-pair difference for change
in zFVC (log-ΔzFVC-changeIP) also identified two
associated probes, with the most highly associated
probe cg12796186 mapping to phosphogluconate
dehydrogenase (PGD) with a p value = 3.28 × 10−6.
Change in zFEV1/FVC (ΔzFEV1/FVC-changeIP) iden-
tified differential methylation at three probes
(Table 4).
In general, the associated findings in both cross-sectional
and longitudinal models showed higher DNA methylation
(relative hyper-methylation) for zFEV1 and zFVC for the
“inferior” twin, whereas lower DNA methylation (relative
hypo-methylation) for zFEV1/FVC was seen for the
“inferior” twin in identified probes (Tables 3 and 4).
Pathway enrichment analyses for GO, KEGG, and PC
were performed on all EWAS results with a p value < 10−5
obtained from both cross-sectional and longitudinal lung
function analyses, and the results are presented in Tables 5
and 6, respectively.
Pathway enrichment analyses for GO, based on top
results from intra-pair difference in level of zFEV1, identi-
fied several enriched pathways (Table 5). The most signifi-
cant were “Negative regulation of bone morphogenetic
protein (BMP) signalling pathway” (BHadj p value = 0.011),
“Ubiquitin protein ligase binding” (BHadj p value = 0.009),
and “Promyelocytic leukaemia protein (PML) body”
(BHadj p value = 0.005). Pathway Commons identified
“Transforming growth factor beta (TGF-β) receptor
Table 2 Lung function values for the cohort with full data
available shown as absolute values (litres (L)), z-scores and intra-
pair differences
Lung function (mean ± SD) Male (n = 172) Female (n = 166)
FEV1 (L) follow-up 3.0 ± 0.7* 2.2 ± 0.5
FVC (L) follow-up 4.1 ± 0.9* 2.9 ± 0.6
FEV1/FVC follow-up 0.80 ± 0.09 0.82 ± 0.07
FEV1-change (L) − 0.45 ± 0.4* − 0.34 ± 0.2
FVC-change (L) − 0.21 ± 0.6 − 0.18 ± 0.4
FEV1/FVC-change 0 0
zFEV1 follow-up − 0.46 ± 1.33 − 0.42 ± 1.18
zFVC follow-up − 0.23 ± 1.23 − 0.15 ± 1.04
zFEV1/FVC follow-up − 0.47 ± 1.19 − 0.53 ± 0.97
zFEV1-change 0.03 ± 0.79 0.14 ± 0.73
zFVC-change 0.45 ± 0.92 0.57 ± 0.82
zFEV1/FVC-change − 0.87 ± 1.18 − 0.86 ± 1.12
Intra-pair (IP) differences
(median (min-max))
(86 pairs) (83 pairs)
ΔzFEV1IP follow-up 0.7 (0.01–5.3) 0.6 (0.002–2.8)
ΔzFVCIP follow-up 0.6 (0.03–4.8) 0.6 (0.02–2.9)
ΔzFEV1/FVCIP follow-up 0.7 (0.02–3.9) 0.5 (0.01–2.5)
ΔzFEV1-changeIP 0.7 (0.005–5.2) 0.5 (0.02–2.9)
ΔzFVC-changeIP 0.7 (0.005–4.7) 0.6 (0.04–3.0)
ΔzFEV1/FVCIP-changeIP 1.1 (0.005–5.7) 1.0 (0.02–4.3)
*p < 0.05 between male and female
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(TGFBR)” to be an enriched pathway for zFEV1
(BHadj p value = 0.045) (Table 5). Several other pathways
driven by the same genes reached statistical significance
(12 pathways with BHadj p value < 0.05) (shown in
Additional file 2: Table S1). Enrichment signal in all
pathways for zFEV1 was driven by SKI (“Sloan-Kettering
Institute”) proto-oncogene in combination with either
BMP binding endothelial regulator (BMPER) or death
domain-associated protein (DAXX). GO and KEGG
pathway analyses for intra-pair difference in level of
zFEV1/FVC identified enriched pathways to be “Protein
homodimerization activity” and “Metabolic pathways”
involving other genes than those highlighted for
zFEV1 and zFVC (Table 5). Additional pathways found in
all enrichment analyses are shown in Additional file 2:
Table S1.
For intra-pair difference in change in lung function, path-
way enrichment analyses identified significant pathways for
ΔzFEV1/FVC-changeIP using Gene Ontology (Table 6).
“Transferase activity” was identified as the most enriched
pathway, driven by the gene xylosyltransferase 1 (GXYLT1)
and DNA polymerase mu (POLM).
Table 3 Overviw of results from EWAS analyses for intra-pair difference in level of lung function at follow-up (p value < 10−5)
Lung function measure Probe Estimate p value Chromosome Bp (hg19) Proximal gene CGI feature Methylationa of
“inferior” twin
Log-ΔzFEV1IP cg04261072 − 0.054 4.33E−06 13 79,977,499 RBM26 Body-shelf Hyper
cg10196163 − 0.062 7.62E−06 14 10,556,0628 NA IGR-shore Hyper
cg12552820 − 0.033 2.69E−06 1 2,231,925 SKI Body-shore Hyper
cg13971574 − 0.037 9.65E−06 2 39,102,874 MORN2 TSS1500-island Hyper
cg18582260 − 0.079 3.99E−06 13 25,085,301 PARP4 5′UTR-shore Hyper
cg20552903 − 0.038 5.81E−06 6 33,289,678 DAXX Body-shore Hyper
cg23759053 − 0.136 5.99E−06 7 34,173,999 BMPER Body-open sea Hyper
cg23840275 − 0.045 2.62E−06 13 20,969,493 NA IGR-shore Hyper
cg27180671 − 0.050 7.51E−06 17 65,527,566 PITPNC1 Body-open sea Hyper
Log-ΔzFVCIP cg00008488 − 0.0935 8.23E−06 5 175,199,915 NA IGR-shore Hyper
cg00306721 − 0.0797 9.54E−06 11 62,477,480 BSCL2 TSS1500-island Hyper
cg01028379 0.0617 2.84E−06 7 4,798,471 FOXK1 Body-shore Hypo
cg02071292 − 0.2366 7.14E−08FDR 12 75,785,097 GLIPR1L2 1stExon-island Hyper
cg07311024 − 0.1553 1.96E−06 12 75,785,089 GLIPR1L2 1stExon-island Hyper
cg15909232 − 0.1167 5.08E−06 7 156,235,420 NA IGR-open sea Hyper
cg15942481 − 0.1366 8.77E−06 12 75,785,230 GLIPR1L2 Body-island Hyper
cg17154159 0.0832 6.02E−06 6 160,401,562 IGF2R Body-open sea Hypo
cg22089890 − 0.0391 4.20E−06 17 48,708,077 NA IGR – shelf Hyper
cg25249300 − 0.0660 1.36E−07 2 54,483,341 TSPYL6 1stExon – island Hyper
ΔzFEV1/FVCIP cg00347643 0.1747 7.88E−06 7 75,957,202 YWHAG 3′UTR-shore Hypo
cg00995220 0.1333 2.13E−07 6 56,259,582 NA IGR-open sea Hypo
cg04697953 0.0849 4.43E−06 2 179,299,404 PRKRA Body-open sea Hypo
cg06244016 0.1917 2.17E−06 6 151,186,511 MTHFD1L TSS200-shore Hypo
cg07219303 0.1575 3.92E−06 4 100,140,905 ADH6 TSS1500-open sea Hypo
cg11980944 0.0863 8.55E−06 1 205,399,731 NA IGR-open sea Hypo
cg13107302 0.0995 5.69E−06 17 75,237,970 NA IGR-open sea Hypo
cg13912599 0.1229 2.66E−06 1 150,959,380 ANXA9 Body-open sea Hypo
cg18221862 − 0.1038 4.81E−06 2 193,059,230 TMEFF2 1stExon-island Hyper
cg18537205 − 0.1205 9.86E−06 10 114,575,091 VTI1A Body-open sea Hyper
cg19529957 0.1367 5.50E−06 7 4,198,590 SDK1 Body-open sea Hypo
Bold indicates significance p < 1 × 10−6. Probes were annotated with the most proximal gene, genomic position Bp (hg19), and CpG island context (CGI feature)
Estimate intra-pair difference in M value (logit-transformed beta), FDR false discovery rate < 0.05, TSS200 region spanning from transcription start site (TSS) to
200 bp upstream of TSS, TSS1500 region spanning from − 200 to − 1500 bp upstream of TSS, 5′UTR 5′ untranslated region, IGR intergenic region, NA not applicable,
Hyper hyper-methylation, Hypo hypo-methylation
aRelative DNA methylation of “inferior” twin compared to “superior” twin
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Discussion
In this study, we investigated possible associations
between lung function and genome-wide DNA methyla-
tion patterns in a population of middle-aged Danish MZ
twin pairs. The lung function of the MADT cohort used
in this study was assessed at two different occasions,
which allowed us to investigate lung function both as
cross-sectional level and as longitudinal change.
The EWAS analyses identified DNA methylation at
several CpG sites associated with intra-pair difference in
level of lung function for the different metrics. The most
significant associated finding for the level of zFVC was
DNA methylation of three CpG sites positioned in the
gene body of GLIPR1L2 in close proximity to each other
(within 150 bp). This gene, situated on chromosome 12,
is a member of the cysteine-rich secretory proteins, anti-
gen 5, and pathogenesis-related 1 proteins (CAP) super-
family. These genes are expressed in the immune tissues
and are involved in a variety of physiological processes,
including innate immunity, inhibition of ion channels
and proteases, and interaction with immunoglobulin
proteins, as well as tumour suppressor and pro-
oncogenic genes in different tissues [79, 80]. The
GLIPR1L2 is a p53 target gene encoding functional p53
response elements that induce tumour suppression [80].
p53 is the most widely and best described tumour sup-
pressor gene known in humans, and p53 mutation is the
most frequently described intermediate step in the path
between smoking and lung cancer [81]. Additionally, as
in this study we did not find any overlap with previous
findings of differentially methylated loci associated with
smoking [53], we feel confident that the adjustment for
smoking status in these EWAS analyses was successful.
However, apart from smoking status of an individual,
other lifestyle choices (such as levels of physical activity)
and environmental factors (such as pollution levels)
impact both lung function levels and epigenetic modifi-
cations [5, 54–56, 82–86]. In the future, collection of
detailed data on environmental factors and lifestyle
choices of investigated individuals may help us identify
epigenetic variation that mediates the effect of these
exposures on lung function in a general population.
For intra-pair difference in change in lung function
during the follow-up period, the EWAS analyses identi-
fied only few CpG sites to be associated with the studied
trait. These were, among others, annotated to genes
encoding cellular enzymes, i.e. PGD, GXYLT1, POLM,
and DEAD box polypeptide 43 (DDX43), also known as
HAGE (DEAD box helicase antigen), of which the latter
has been shown to be an immunogenic cancer-specific
antigen present in the protein level of different tumours
including lung cancers [87]. Also, the methylation of
TRIM27, a negative regulator of CD4 T cells [88] also
involved in the development of cancer [89], was identi-
fied to be associated with change in lung function over
the 11-year period.
The observed discrepancy in directions of level of DNA
methylation within twin pairs (hypo-/hyper-methylation)
for the different lung function measures (Tables 3 and 4)
may illustrate differences in level of activation of inflamma-
tory genes and pathways, especially for zFEV1/FVC, for
which inflammation is known to be an important factor.
Pathway enrichment analyses showed several significant
pathways of interest for the level of lung function. “Negative
regulation of BMP signalling pathway” involving the genes
BMPER and SKI and “TGFBR” pathway involving DAXX
and SKI were enriched pathways for intra-pair difference in
level of zFEV1. These pathways are involved in malignant
tumour growth and metastasis [90, 91] and angiogenesis
[92], and TGF-β plays an important role for normal lung
morphogenesis and hence lung function [93]. TGF-β
is involved in normal lung tissue repair in adults through
its pro-fibrotic effects; however, over-expression of TGF-β
is associated with different lung diseases, including
lung fibrosis [93, 94]. Another possible mechanism
for regulating the activity of TGF-β is the expression
Table 4 Overview of results from EWAS analyses for intra-pair difference in change in lung function during the follow-up period
(p value < 10−5)
Lung function measure Probe Estimate p value Chromosome Bp (hg19) Proximal gene CGI feature Methylationa of “inferior” twin
Log-ΔzFEV1-changeIP cg19484381 − 0.055 1.55E−06 6 28,890,673 TRIM27 Body-shore Hyper
cg27261494 − 0.081 5.77E−06 6 74,104,097 DDX43 TSS200-shore Hyper
Log-ΔzFVC-changeIP cg12796186 − 0.066 3.28E−06 1 10,458,599 PGD TSS1500-island Hyper
cg14514174 − 0.044 6.39E−06 9 99,181,512 ZNF367 TSS1500-island Hyper
ΔzFEV1/FVC-changeIP cg00552805 0.0551 9.84E−06 7 44,119,858 POLM Body-shore Hypo
cg06375580 0.0449 9.25E−06 12 42,538,820 GXYLT1 TSS200-island Hypo
cg12733656 0.0396 8.82E−06 7 6,388,695 C7orf70 TSS200-island Hypo
Bold indicates significance p < 1 × 10−6. Probes were annotated with the most proximal gene, genomic position Bp (hg19), and CpG island context (CGI feature)
Estimate intra-pair difference in M value (logit-transformed beta), TSS200 region spanning from transcription start site (TSS) to 200 bp upstream of TSS, TSS1500
region spanning from − 200 to − 1500 bp upstream of TSS, 5′UTR 5′ untranslated region, IGR intergenic region, NA not applicable, hyper hyper-methylation,
hypo hypo-methylation
aRelative DNA methylation of “inferior” twin compared to “superior” twin
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of the TGF-β receptors [93], making it plausible that
the TGFBR pathway is of high importance for lung
function. These findings suggest that DNA methylation of
oncogenic- and tumour suppressor-related genes, as well
as TGF-β-receptor-related genes, could be involved in the
level and change in lung function.
Other studies similarly reported significant association
between DNA methylation and lung function, however,
Fig. 1 Manhattan plots depicting results from all six EWAS analyses
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not within the same genes and not involving the same
pathways as found in this study, though most of the
genes studied previously are included in the 450
BeadChips used in this study. Lepeule et al. [61]
explored the association between the DNA methylation
of nine specific inflammatory genes and the lung func-
tion level in a cohort of elderly Caucasian men.
Decreased DNA methylation in the inflammatory genes
CRAT, F3, and TLR2 was shown to be associated with
lower level of lung function (FEV1 and FVC).
Oppositely, decreased DNA methylation in IFNγ and
IL6 was associated with better lung function, insinuating
that these genes may be involved in activation of
negative feedback in the inflammatory pathways [61].
Qiu et al. [62] identified 349 CpG sites significantly asso-
ciated to lung function, of which 330 were hypo-
methylated in the presence of lower lung function.
Hypo-methylation of CpG sites in SERPINA1 was nega-
tively associated to both FEV1 and FEV1/FVC, and this
was replicated in another cohort. This gene encodes the
acute-phase reactant ɑ1-antitrypsin, a potent circulating
anti-elastase produced in the liver but transported to the
lung. Variation in the ɑ1-antitrypsin gene SERPINA1 is
known to be a monogenic cause of COPD [95], as defi-
ciency of ɑ1-antitrypsin leads to failing maintenance of
the structural integrity of the lung. Other top
associations for CpG sites found by Qiu et al. were in
ATP6V1E2, FXYD1, FUT7, and STAT5A for FEV1 and
in ATP6V1E2, FXYD1, TRPM2, and LRP3 for the FEV1/
FVC ratio [62] with no overlap to our study. The specific
associations between DNA methylation of the repetitive
elements Alu and LINE-1 and lung function was studied
in the Veterans Administration Normative Aging Study
of older Caucasian men [63]. Hypo-methylation of Alu
and LINE-1 was associated to lower cross-sectional
FEV1 level. Faster rate of decline in FEV1 and FVC was
associated with relative hypo-methylation in LINE-1
(p < 0.005), but not in Alu. The mechanism behind this
association was suggested to be that hypo-methylation
may increase the activity of the repetitive elements as
retro-transposable sequences, leading to greater genomic
instability and more mutations, which in turn may lead
to adverse effects on lung function and lung function
decline [63]. However, as the above-mentioned previous
studies were performed on a general population and not
on twin samples, their results may be driven by an
underlying genetic component. Our study, comparing
intra-pair methylation differences in MZ twins, accounts
for the genetic factor for lung function and for DNA
methylation levels.
It should be noted that blood samples from the partic-
ipants in this study were collected only at follow-up.
Table 5 Pathway enrichment analyses for Gene Ontology (GO), KEGG, and Pathway Commons (PC) (separate pathways with
BH-corrected p value < 0.1) based on significant findings from EWAS for level of lung function
Lung function
measure
Database Pathway name No. of
genes
Genes Statistics
Log-ΔzFEV1IP GO Negative regulation of BMP
signaling pathway
2 BMPER SKI C= 32; O= 2; E= 0.01; R= 142.86; rawP= 7.87e-05; adjP = 0.0114
Ubiquitin protein ligase
binding
2 DAXX SKI C= 147; O= 2; E= 0.05; R= 38.69; rawP= 0.0010; adjP = 0.0090
PML body 2 DAXX SKI C = 72; O = 2; E = 0.02; R = 87.37; rawP = 0.0002; adjP = 0.0052
PC TGFBR 2 DAXX SKI C= 125; O= 2; E= 0.05; R= 43.92; rawP= 0.0009; adjP = 0.0450
Log-ΔzFVCIP No significant pathway enrichment
results
ΔzFEV1/FVCIP GO Protein homodimerization
activity
3 MTHFD1L ANXA9 PRKRA C= 554; O= 3; E= 0.27; R= 11.00; rawP= 0.0018; adjP = 0.0324
KEGG Metabolic pathways 2 ADH6 MTHFD1L C = 1093; O = 2; E = 0.46; R = 4.39; rawP = 0.0720; adjP = 0.0720
Bold indicates BH adjP < 0.05
C the number of reference genes in the category, O the number of genes in the gene set and also in the category, E the expected number in the category, R ratio
of enrichment, rawP p value from hypergeometric test, adjP p value adjusted by the multiple test adjustment (BH)
Table 6 Pathway enrichment analyses for Gene Ontology (GO), KEGG, and Pathway Commons (PC) (separate pathways with BH-
corrected p value < 0.1) based on significant findings from EWAS for change in lung function
Lung function measure Database Pathway name No. of genes Genes Statistics
Log-ΔzFEV1-changeIP No significant pathway enrichment results
Log-ΔzFVC-changeIP No significant pathway enrichment results
ΔzFEV1/FVC-changeIP GO Transferase activity 2 GXYLT1 POLM C = 1641; O = 2; E = 0.23; R = 8.67; rawP = 0.0133; adjP = 0.0399
Bold indicates BH adjP < 0.05
C the number of reference genes in the category; O: the number of genes in the gene set and also in the category, E the expected number in the category, R
ratio of enrichment, rawP p value from hypergeometric test, adjP p value adjusted by the multiple test adjustment (BH)
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Accordingly, it was only possible to correlate longitu-
dinal lung function change with DNA methylation status
at follow-up and not with DNA methylation changes
over time. Thus, although significant associations have
been found between DNA methylation and lung func-
tion, the direction of causality cannot be inferred. How-
ever, biologically plausible hypotheses may suggest the
direction of causality. The possible mechanism behind a
causal relation may be that environmental exposures
induce oxidative damage and changes in DNA methyla-
tion, which may in turn impact lung function due to
altered gene expression, as also suggested by Lepeule
et al. [63]. Additionally, as there is an increasing
evidence suggesting association between smoking,
histone modifications (e.g. histone acetylation), and lung
function, future investigation of DNA methylation
alongside with other epigenetic modifications and
epigenome-modifying proteins (such as DNMTs, TETs,
histone acetylases, and deacetylases) is warranted in
order to reach deeper understanding of the role of epi-
genetics in lung function.
A possible limitation of this study is that DNA methy-
lation was measured in leukocytes, as blood is an easily
accessible biological sample. In this study, we adjusted
all our analyses for blood cell counts measured with the
use of flow cytometry for all individuals, and thus, we
believe that our results are not cofounded by the blood
cellular heterogeneity. Whether or not the identified
methylation differences reflect differential processes also
occurring in the lung tissue is not clear. However, leuko-
cytes infiltrate the lung tissue and neutrophil inflamma-
tion can be an early component of lung function decline
[61]. Furthermore, inflammatory cytokines have been
shown to be elevated in circulating blood of COPD
patients [96], suggesting a “spill-over” of cytokines from
the lung tissue to the systemic circulation. This may also
happen as part of the recruitment of leukocytes to the
lungs in association with different inhalable exposures
[97, 98]. DNA methylation levels of genes expressed in
leukocytes may therefore be a relevant marker of e.g.
inflammatory processes in the lungs. Chronic pulmonary
diseases, such as asthma and COPD, are among the ten
top leading causes of years’ lost due to disability world-
wide and are associated with decreased lung function
and accelerated lung function decline [99–103]. Due to
the high prevalence of these diseases in a population, it
is possible that the measurement of lung function in our
investigated population reflected COPD or asthma diag-
nosis and thus that the differentially methylated sites
identify loci associated with chronic pulmonary diseases.
In the future, collection of detailed information on diag-
nosis and trajectory of chronic pulmonary diseases,
alongside with FEV1 and FVC measures for the studied
population, may help us delineate if the identified
differentially methylated loci are also associated with
chronic pulmonary diseases.
The observed cross-sectional lung function phenotype
(z-score level) for this cohort was lower than expected
for the population, while the z-score increased during
the follow-up period in comparison to the GLI 2012 ref-
erence population. There might be several reasons for
these cross-sectional and longitudinal differences. Firstly,
different spirometer devices were used, and secondly,
the increase in z-score during the follow-up period may
be due to discrepancies when comparing longitudinal
lung function change with that estimated from cross-
sectional lung function prediction equations, possibly
due to cohort effects as reported before [104]. However,
we expect any possible misclassifications to be of non-
differential type. The rate of absolute lung function
decline for this age group was similar to what has been
reported in previous studies [82, 83, 105].
As for generalizability to other populations, it must be
emphasized that this unique cohort consisted of middle-
aged Caucasian MZ twins with the unique opportunity
to control for underlying genetic background, shared
environment, and blood cell composition effects. How
DNA methylation in younger cohorts and of other
ethnicities would be associated with lung function still
remains to be explored. Validation is further needed in
order to ensure strength and relevance of our results.
Conclusions
In conclusion, this study shows that DNA methylation
patterns in blood are associated with the level and
change in lung function in MZ twin pairs, identifying
several CpG sites and biological pathways of possible
importance for lung function. Specifically, oncogenic- and
tumor suppressor-related genes (GLIPR1L2, BMPER, SKI,
and DAXX), as well as TGF-β-receptor-related genes,
could be involved in cross-sectional level and longitudinal
change in lung function. All these findings point to bio-
logical pathways of potential importance for pulmonary
physiology.
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